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ABSTRACT
Objective To provide an overviewof drug use in children in
three European countries.
Design Retrospective cohort study, 2000-5.
Setting Primary care research databases in the
Netherlands (IPCI), United Kingdom (IMS-DA), and Italy
(Pedianet).
Participants 675868 children aged up to 14 (Italy) or 18
(UK and Netherlands).
Main outcome measure Prevalence of use per year
calculated by drug class (anatomical and therapeutic).
Prevalence of “recurrent/chronic” use (three or more
prescriptions a year) and “non-recurrent” or “acute” use
(less than three prescriptions a year) within each
therapeutic class. Descriptions of the top five most
commonly used drugs evaluated for off label statuswithin
each anatomical class.
Results Three levels of drug use could be distinguished in
the study population: high (>10/100 children per year),
moderate (1-10/100 children per year), and low (<1/100
children per year). For all age categories, anti-infective,
dermatological, and respiratory drugswere in thehighuse
group, whereas cardiovascular and antineoplastic drugs
were always in the low use group. Emollients, topical
steroids, and asthma drugs had the highest prevalence of
recurrentuse, but relativeuseof lowprevalencedrugswas
more often recurrent than acute. In the top five highest
prevalence drugs topical inhaled and systemic steroids,
oral contraceptives, and topical or systemic antifungal
drugs were most commonly used off label.
Conclusion This overview of outpatient paediatric
prescription patterns in a large European population
could provide information to prioritise paediatric
therapeutic research needs.
INTRODUCTION
Recent years have seen growing concerns about the
incompleteness of the evidence relating to the efficacy
and safety of drugs used in children. Almost all of the
drugs prescribed to children are the same as those
originally developed for adults. They are often
prescribed on an unlicensed or “off label” basis
(percentages ranging from 11-80%1) simply by extra-
polating data for adults, without conducting any
paediatric clinical, kinetic, dose finding, or formulation
studies in children. Diseases in children, however,
might be different from their adult equivalents, and the
processes underlying growth and development might
lead to a different effect or an adverse drug reaction
unseen in adults (Reye’s syndrome is an outstanding
example).
To provide legitimate and appropriate treatment for
children’s diseases, new legislationwasapproved in the
United States in 2003 and the European Union in
2007.2 Both the Food and Drug Administration (FDA)
and the European Medicines Agency for the Evalua-
tion of Medicinal Products (EMEA) now offer exten-
sions of drug licences to companies who provide
evidence concerning the efficacy and safety in children
of new drugs or off label drugs.3-6 The World Health
Organization underlines the need for these actions and
in December 2007 launched a global campaign to
“make medicines child size” to address the need for
improved availability and access to safe child specific
medicines for all children.7
We investigated the current useof paediatric drugs in
children in threeEuropean countries, usingpopulation
based data on primary care prescriptions.
METHODS
Setting
The primary care of children is entrusted to general
practitioners in the UK and the Netherlands and to
paediatricians in Italy.8 9 Access to health care is free in
Italy and the UK and fully covered by healthcare
insurance in the Netherlands. In these countries,
primary care physicians are responsible for children’s
health care, which means that all clinical information
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concerning the patients (including summaries of
specialist and hospital care) is kept in their medical
records. As all children need to be registered with a
general practitioner in the Netherlands and UK and
with a family paediatrician in Italy, the databases are
population based.9
Data collection
We used the same protocol to study prescription
patterns in the three countries, making use of the
Pedianet database (paediatric electronic medical
records from 150 paediatricians since 2000) in Italy,10
the integrated primary care information (IPCI) data-
base (comprising adult and paediatric electronic
medical records from more than 400 doctors since
1996) in the Netherlands,8 11 12 and the IMS disease
analyser database (IMS-DA: electronic medical
records on adults and children from670 doctors) in the
UK.13 All of these databases include the complete
automatedmedical records of primary care physicians
and have been used and proved valid for pharmacoe-
pidemiological research.9 The age and sex distribution
in the various databases is representative for the
country of origin.
Study population and drug prescriptions
The dynamic study population in each country
consisted of all children aged 0-18 years (0-14 years
in Italy) who had a database history of at least six
months or who were born during the study period (1
January2000 to31December2005).We calculated the
person time of follow-up for each child, stratified by
calendar year and age group. Age was assessed on 1
January of each year and grouped according to the
guidelines of the International Conference of Harmo-
nization (ICH) as <2, 2-11, and 12-18.14 We could not
further stratify the youngest age category into new-
borns (<1 month) and infants (1-24 months) as exact
dates of birth were not available because of privacy
regulations. Each child was followed from the start of
the study period or the date of registration with the
primary practice (whichever was the latest) until the
cancellation of registration with the practice or the end
of the study period. We used the person time
accumulated in each calendar year as the denominator
to calculate prevalence rates. Over the study period
children could contribute to more than one age
category.
All prescribed drugs in children during follow-up
were retrieved from the prescription data in the
database. The drug prescriptions were grouped on
the basis of the WHO Anatomical Therapeutic
Chemical (ATC) classification system, which made
comparison between countries possible.
Statistical analysis
We estimated user prevalence rates (per 1000 person
years) by counting the number of children using a
specific drug in a specific calendar year. The pre-
valence rates were calculated by age and country to
account for differences in distributions between
populations and to allow for direct comparisons within
groups. User prevalence rates should be interpreted as
the number of children per 1000 who use a specific
class of drug in one year. We could not calculate
prevalence of drug use for children aged 15-18 in Italy
because all of children were censored at the age of 15.
We used person years rather than individuals as the
denominator because of the dynamic nature of age and
the population.
For each anatomical class of drugwe assessed the age
and country specific user prevalence rates for all
individual drugs in 2005. We evaluated the five drugs
with the highest prevalence per anatomical class in
each country for off label status considering ageonly.A
drug was considered to be off label for age if the child’s
age at the time of use was below the lowest approved
age mentioned in the summary of product character-
istics of that drug in each country.15 Within each
therapeutic drug level, we separately estimated the
prevalence of children presenting “recurrent/chronic”
(three or more prescriptions a year) versus “non-
recurrent” or “acute” drug use (less than three
prescriptions a year), and the ratio between them to
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Fig 1 | One year prevalence of drug prescriptions by age (<2, 2-11, 12-18 years), and anatomical class
RESEARCH
page 2 of 13 BMJ | ONLINE FIRST | bmj.com
identify the treatments more commonly used for
chronic than acute paediatric diseases. We used χ2
test to compare user prevalence rates.
RESULTS
Study population
Our population of 675 868 children generated
2 334 673 person years of follow-up (table 1); the
mean individual follow-up was 3.5 years. Most of the
children (66%) came from the IMSdatabase in theUK,
19% from Italy, and 15% from the Netherlands. The
databases recorded more than five million paediatric
prescriptions. In all three countries the prescription
rate was highest for the children aged under 2 and, in
each age group, was significantly higher in the UK and
Italy than in the Netherlands (P<0.001) (table 1).
Drug use by anatomical class
The highest prevalence rates among the children aged
under 2 were for anti-infective drugs, respiratory drugs,
and dermatological drugs, which were used by 48%,
30%, and 30% of the children, respectively (fig 1). The
other common prescriptions were for gastrointestinal
drugs (user prevalence of 20%), drugs for the nervous
system (14%) and drugs for sensory organs (19%). Blood
and blood forming organs, hormonal, and musculoske-
letal system drugs were used in 1-10% of the children,
and cardiovascular, genitourinary, antineoplastic, and
antiparasitic drugs by less than 1%.
Among the children aged 2-11, the prevalence of use
of anti-infective, respiratory, and dermatological drugs
decreased to 30%, 21%, and 17%, respectively. The
prevalence was 1-10% for gastrointestinal, hormonal,
musculoskeletal system, nervous system, antiparasitic,
and sensory organ drugs; and less than 1% for blood
and blood forming organs, cardiovascular, genitour-
inary, and antineoplastic drugs.
In adolescents (12-18 years), anti-infective, respira-
tory, anddermatological drugswere usedbymore than
10% per year.Most of the other drug classes were used
by 1-10%, but the prevalence of use of cardiovascular
and antineoplastic drugs was less than 1%.
Regarding sex differences, in the youngest age
groups, most of the drugs were equally prescribed to
both sexes ormore commonly prescribed to boys than
girls (rate ratio <1), particularly anti-infective and
respiratory drugs. This pattern reversed in adoles-
cence, when user prevalence for almost all drug classes
(except non-sex hormones) was higher among girls
than boys. This sex pattern, which was consistent
across countries, was most pronounced for genitour-
inary drugs, with a user prevalencemore than 60 times
higher ingirlsbecause they includeoral contraceptives,
which accounted for 95% of the use of genitourinary
drugs in girls. The use of drugs for blood and blood
forming organs (mainly iron preparations) was also
markedly higher among adolescent girls.
The age trend of prevalence of use was consistent
across countries, although there were some variations in
the age specific rates (fig 2). Inparticular, theUKshowed
thehighest prevalenceof alimentarydruguse in children
aged under 2, and the prevalence of prescriptions of
dermatological drugs was threefold to fourfold higher in
theUKand theNetherlands than in Italy (bothP<0.001).
Theprevalenceof genitourinarydruguse (almost all oral
contraceptives) was high in adolescent girls in the
Netherlands (P<0.001). In Italy, the use of hormones
(almostall systemiccorticosteroids)was10-foldhigher in
children aged <2 (P<0.001) and fivefold higher in those
aged 2-11 (P<0.001); respiratory drug use was also
greater in Italy than in theother two countries (P<0.001).
The prevalence of the use of anti-infective drugs and
drugs for musculoskeletal disorders was much lower in
the Netherlands; the prevalence of prescriptions for
Table 1 | Characteristics of study population
Patients No of children*
No (%) of person
years No of prescriptions
Prescriptions/
person year
Italy
<2 years 56 000 87 408 (22) 286 597 3.3
2-11 years 103 195 296 148 (73) 690 688 2.3
12-14 years 18 154 22 599 (6) 35 883 1.6
Females 61 962 194 744 (48) 462 580 2.4
Males 67 525 211 412 (52) 550 588 2.6
2000 11 188 369 (0) 1150 3.1
2001 73 364 45 330 (11) 140 764 3.1
2002 95 712 78 850 (19) 220 207 2.8
2003 103 987 94 131 (23) 242 261 2.6
2004 106 555 96 388 (24) 206 535 2.1
2005 102 911 91 086 (22) 202 251 2.2
Total 129 487 406 156 (100) 1 013 168 2.5
UK
<2 years 95 060 106 250 (6) 494 353 4.7
2-11 years 262 306 855 678 (52) 2 011 153 2.4
12-18 years† 229 959 683 900 (42) 1 549 372 2.3
Females 219 669 804 646 (49) 2 047 616 2.5
Males 225 153 841 182 (51) 2 007 262 2.4
2000 307 884 288 450 (18) 659 067 2.3
2001 306 923 286 483 (17) 677 373 2.4
2002 305 088 285 664 (17) 670 690 2.3
2003 303 594 280 085 (17) 679 216 2.4
2004 287 287 259 219 (16) 674 389 2.6
2005 265 273 245 927 (15) 694 143 2.8
Total 444 822 1 645 828 (100) 4 054 878 2.5
Netherlands
<2 years 25 694 36 601 (13) 78 983 2.2
2-11 years 62 326 159 010 (56) 208 134 1.3
12-18 years 40 364 87 078 (31) 147 250 1.7
Females 49 709 138 262 (49) 230 466 1.7
Males 51 850 144 427 (51) 203 901 1.4
2000 56 423 48 752 (17) 76 319 1.6
2001 53 274 46 822 (17) 76 059 1.6
2002 57 998 50 219 (18) 81 919 1.6
2003 62 216 49 279 (17) 73 462 1.5
2004 60 315 50 882 (18) 75 399 1.5
2005 52 252 36 735 (13) 51 209 1.4
Total 101 559 282 689 (100) 434 367 1.5
*Number of children in various age groups does not add up to total as one child can contribute to more than one
category.
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Table 2 | Prevalence of acute use (<3 prescriptions per year) and recurrent use (≥3 prescriptions per year) by age and therapeutic level (prevalence per 1000
person years), ranked by the ratio of recurrent to acute use*
Anatomical and therapeutic class (ATC)
Acute use Recurrent use Ratio recurrent/
acute
Total
prevalence<2 2-11 12-18 All ages <2 2-11 12-18 All ages
Gastrointestinal
Drugs used in diabetes (A10) 0.0 0.2 0.3 0.2 0.0 0.9 2.5 1.3 7.0 1.5
Digestives, including enzymes (A09) 0.1 0.0 0.0 0.0 0.1 0.2 0.2 0.2 4.9 0.2
Bile and liver therapy (A05) 0.1 0.0 0.0 0.0 0.1 0.1 0.1 0.1 1.7 0.1
Mineral supplements (A12 1.1 0.8 0.5 0.7 0.2 0.3 0.2 0.2 0.3 1.0
Laxatives (A06) 24.7 13.3 6.2 12.0 3.3 4.7 1.8 3.6 0.3 15.6
Drugs for acid related disorders (A02) 27.0 3.5 9.6 7.9 12.6 0.8 1.7 2.3 0.3 10.1
Vitamins (A11) 24.2 3.6 1.4 4.9 3.5 0.7 0.5 0.9 0.2 5.8
Antiemetics and antinausea (A04) 1.4 0.6 3.7 1.8 0.7 0.1 0.2 0.2 0.1 2.0
Drugs for functional gastrointestinal disorders (A03) 25.9 10.6 9.7 11.8 1.4 0.4 0.9 0.6 0.1 12.4
Stomatological preparations (A01) 56.3 6.6 4.2 10.7 3.2 0.2 0.2 0.5 0.0 11.2
Antidiarrhoeal (A07) 64.9 11.6 3.2 14.0 1.9 0.3 0.6 0.5 0.0 14.5
Blood and blood forming organs
Antithrombotic agents (B01) 0.2 0.2 0.3 0.3 0.2 0.3 0.3 0.3 1.1 0.5
Antianaemic preparations (B03 20.8 3.6 6.8 6.4 2.9 0.5 1.2 1.0 0.2 7.4
Antihaemorrhagics (B02) 5.5 1.0 1.6 1.6 0.2 0.1 0.2 0.1 0.1 1.8
Cardiovascular system
Agents acting on renin-angiotensin system (C09) 0.1 0.1 0.1 0.1 0.1 0.2 0.3 0.2 2.5 0.3
Lipid modifying agents (C10) 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.1 1.7 0.1
Diuretics (C03) 0.6 0.1 0.1 0.2 0.6 0.1 0.2 0.2 1.2 0.4
Calcium channel blockers (C08 0.0 0.0 0.2 0.1 0.0 0.0 0.2 0.1 0.8 0.2
β blocking agents (C07 0.1 0.2 2.2 0.8 0.1 0.2 0.7 0.3 0.4 1.2
Cardiac therapy (C01) 1.3 2.2 1.6 1.9 0.2 0.3 0.3 0.3 0.2 2.2
Dermatological
Anti-acne preparations (D10) 0.3 1.0 31.2 11.2 0.0 0.1 15.0 5.2 0.5 16.3
Emollients and protectives (D02) 98.8 45.1 25.6 43.8 48.5 21.8 8.1 19.8 0.5 63.6
Antipsoriatics (D05) 3.9 3.1 4.8 3.7 0.2 0.5 2.0 1.0 0.3 4.7
Corticosteroids, dermatological preparations (D07) 140.4 74.1 55.9 74.4 24.4 11.9 8.7 12.0 0.2 86.5
Preparations for treatment of wounds and ulcers
(D03)
1.1 0.7 1.0 0.8 0.0 0.1 0.1 0.1 0.1 0.9
Antiseptics and disinfectants (D08) 3.9 2.4 2.8 2.7 0.1 0.1 0.2 0.1 0.1 2.8
Antifungals for dermatological use (D01) 50.8 18.4 19.6 22.0 1.6 0.6 1.5 1.0 0.0 23.0
Antibiotics and chemotherapeutics (D06) 43.6 36.4 23.6 32.8 0.8 0.9 0.9 0.9 0.0 33.7
Other dermatological preparations (D11) 5.3 8.9 9.8 8.9 0.2 0.1 0.4 0.2 0.0 9.1
Genitourinary system and sex hormones
Sex hormones, modulators of genital system (G03) 1.7 0.4 32.3 11.3 0.3 0.1 49.7 17.0 1.5 28.3
Urologicals (G04) 0.5 1.1 1.8 1.3 0.1 0.6 0.6 0.5 0.4 1.8
Gynaecological anti-infectives and antiseptics (G01) 1.1 1.3 9.2 4.0 0.0 0.0 0.5 0.2 0.0 4.2
Systemic hormonal preparations, excluding sex hormones and insulins
Thyroid therapy (H03) 0.3 0.2 0.3 0.2 0.4 0.5 1.1 0.7 3.1 0.9
Pituitary and hypothalamic hormones (H01) 0.1 2.2 1.5 1.7 0.0 1.3 1.4 1.2 0.7 3.0
Corticosteroids for systemic use (H02) 51.0 23.2 8.0 20.7 6.0 2.2 1.0 2.2 0.1 22.9
Pancreatic hormones (H04) 0.0 0.3 0.7 0.4 0.0 0.0 0.1 0.0 0.1 0.4
Anti-infectives for systemic use
Antibacterials for systemic use (J01) 340.0 241.4 166.3 225.6 95.2 47.0 27.6 45.2 0.2 270.7
Antimycobacterials (J04) 0.5 0.5 0.3 0.4 0.1 0.0 0.0 0.0 0.1 0.5
Vaccines (excluding routine childhood vaccinations)
(J07)
11.8 10.6 14.3 12.0 0.8 0.4 1.0 0.6 0.1 12.6
Antimycotics for systemic use (J02) 1.1 0.6 3.7 1.7 0.0 0.0 0.2 0.1 0.0 1.8
Antivirals for systemic use (J05) 9.8 4.2 1.7 3.9 0.1 0.0 0.1 0.1 0.0 4.0
Antineoplastic and immunomodulating drugs
Immunosuppressive agents (L04) 0.0 0.0 0.1 0.1 0.0 0.1 0.4 0.2 3.8 0.3
Antineoplastic agents (L01) 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.9 0.2
Musculoskeletal system
Muscle relaxants (M03) 0.1 0.1 0.2 0.1 0.0 0.1 0.2 0.2 1.7 0.2
Anti-inflammatory and antirheumatic products
(M01)
38.8 32.0 53.6 40.0 1.2 1.2 3.0 1.8 0.0 41.8
Nervous system
Antiepileptics (N03) 0.7 0.7 0.8 0.7 1.1 2.6 3.6 2.8 3.9 3.5
Psychoanaleptics (N06) 0.1 1.1 6.8 2.9 0.0 1.7 6.8 3.3 1.1 6.2
Table 2 cont at the top of the next page
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drugs for the nervous system (including paracetamol,
which can be prescribed in UK) was much higher in the
UK; and the use of drugs for the sensory organs was
much less in Italy.
Prevalence of drug use in therapeutic class
Within the most commonly used anatomical drug
classes, antibacterials accounted for most of the anti-
infective drug use; and the therapeutic classes anti-
asthmatics, other respiratory products, and nasal pre-
parations were the most commonly used drugs in the
respiratory group (table 2). The therapeutic classes with
the highest prevalence of use among the dermatological
drugs were topical corticosteroids and emollients and
barrier creams.Many therapeutic classes in the group of
alimentary drugs (laxatives, antidiarrhoeal drugs, drugs
for acid disorders) had a considerable prevalence of use.
The most commonly prescribed drugs in the other
classes were antianemia medications, cardiac drugs
(mainly digoxin), sex hormones, oral corticosteroids,
non-steroidal anti-inflammatory drugs, analgesics, and
ophthalmological drugs.
Rankingof userprevalence rates specific for ageover
the entire range of drugs showed that antibacterials are
the most commonly prescribed drugs in all age groups
(table 3) and are prescribed to at least twice as many
children as the second most commonly used drug in
each age category. The second most commonly used
drug changed by age from ophthalmological drugs (<
2years) to drugs for obstructive airwaydisease (2-11) to
sex hormones (12-18).
When we ranked the therapeutic classes within each
anatomical class on the basis of the ratio between
recurrent (chronic) and non-recurrent (acute), we
observed a different pattern (table 2). The drugs with
a ratio of >1 (indicating mostly chronic/recurrent use)
were often those with a low prevalence of use (except
for sex hormones): antidiabetics, digestives, bile and
liver therapy, antithrombotic agents, agents acting on
the renin-angiotensin system, lipid lowering drugs, sex
hormones, thyroid therapeutic agents, immunosup-
pressive agents, muscle relaxants, antiepileptics, and
psychoanaleptics (table 2). In absolute terms, emolli-
ents, topical corticosteroids, sex hormones, anti-
infectives, and drugs for obstructive airway disease
showed the highest prevalence of recurrent use.
Most commonly used drugs in each anatomical class
In the most commonly used anatomical classes
(dermatology, anti-infectives, and respiratory system),
Anatomical and therapeutic class (ATC)
Acute use Recurrent use Ratio recurrent/
acute
Total
prevalence<2 2-11 12-18 All ages <2 2-11 12-18 All ages
Antiparkinsonian (N04) 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 1.1 0.1
Psycholeptics (N05) 7.3 2.2 5.0 3.6 0.4 0.4 1.6 0.8 0.2 4.5
Other nervous system drugs (N07) 0.1 0.2 2.0 0.8 0.0 0.0 0.4 0.2 0.2 1.0
Analgesics (N02) 109.9 55.0 38.7 54.9 24.2 8.5 5.6 9.0 0.2 63.9
Anaesthetics (N01) 2.1 4.2 4.2 4.0 0.1 0.1 0.2 0.1 0.0 4.1
Antiparasitic products
Ectoparasiticides (P03) 2.9 14.9 10.6 12.2 0.1 1.5 0.8 1.1 0.1 13.4
Antiprotozoals (P01) 1.8 1.7 2.2 1.9 0.0 0.0 0.0 0.0 0.0 1.9
Anthelmintics (P02) 4.4 12.2 3.1 8.4 0.1 0.2 0.0 0.1 0.0 8.5
Respiratory system
Drugs for obstructive airway diseases (R03) 126.3 69.3 39.2 64.7 34.8 39.1 31.8 36.2 0.6 100.9
Other respiratory system products (R07) 45.4 55.1 53.0 53.4 2.8 8.1 14.1 9.6 0.2 63.0
Antihistamines for systemic use (R06) 50.4 29.1 17.4 27.3 3.5 2.1 2.6 2.4 0.1 29.7
Nasal preparations (R01) 79.1 36.2 43.7 43.0 3.9 2.1 4.4 3.1 0.1 46.1
Cough and cold preparations (R05) 4.1 2.2 1.7 2.2 0.2 0.1 0.0 0.1 0.0 2.3
Throat preparations (R02) 1.1 1.4 4.0 2.3 0.0 0.0 0.1 0.0 0.0 2.3
Sensory system
Ophthalmological (S01) 164.9 60.7 42.9 64.9 10.3 3.1 4.0 4.1 0.1 69.0
Ophthalmological and otological preparations (S03) 3.2 3.5 4.0 3.7 0.1 0.2 0.1 0.1 0.0 3.8
Otological (S02) 15.7 15.0 13.5 14.6 0.4 0.5 0.6 0.5 0.0 15.1
ATC=WHO Anatomical Therapeutic Chemical classification system.
*Excluding therapeutic levels with prevalence of both acute and recurrent use <0.1/1000 person years.
Pr
ev
al
en
ce
 p
er
 1
00
0 
pe
rs
on
 y
ea
rs
Al
im
en
ta
ry
De
rm
at
olo
gic
al
Ge
ni
to
ur
ina
ry
Ho
rm
on
es
An
ti-
in
fe
cti
ve
s
Mu
sc
ulo
sk
ele
ta
l
Ne
rvo
us
 sy
ste
m
Re
sp
ira
to
ry
Se
ns
or
y o
rg
an
s
0
300
600
900
1200
1500
<2
2-
11
12
-1
8 <2
2-
11
12
-1
8 <2
2-
11
12
-1
8 <2
2-
11
12
-1
8 <2
2-
11
12
-1
8 <2
2-
11
12
-1
8 <2
2-
11
12
-1
8 <2
2-
11
12
-1
8 <2
2-
11
12
-1
8
Age group (years)
UK Netherlands Italy
Fig 2 | Year prevalence of drug use (per 1000 person years) by age (<2, 2-11, 12-18), country, and
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the most common individual dermatological drugs
were fusidic acid (except for Italy), topical steroids, and
topical imidazole/triazole derivatives (tables 4, 5, and
6). The topical triazoles/imidazoles were off label in
most countries for at least one or more age categories.
In the anti-infectives group (J), penicillin derivatives
(amoxicillin, co-amoxiclav, and phenoxymethylpeni-
cillin) followed by macrolides (erythromycin, clari-
thromycin) were the most common, cefalexin (UK,
<2 year) was the only off label drug.Oral aciclovir was
one of the top five anti-infective drugs in Italy. Among
the respiratory drugs, salbutamol and inhaled steroids
(beclometasone, fluticasone, flunisolide), anti-
histamines (cetirizine, loratidine, clorpheniramine),
and xylometazoline were most commonly prescribed.
Beclometasone, xylometazoline, and cetirizine were
off label in the youngest children (<2 years) in the UK
and the Netherlands.
In the moderately used drugs (gastrointestinal,
genitourinary, nervous system, and sensory system
drugs), themost commonlyprescribedalimentary tract
drugs (A) were laxatives (lactulose), miconazole,
domperidone, and mebeverine. Only ranitidine and
laurilsulfate were off label in children <2 years. For the
genitourinary drugs, the top five in the Netherlands
and UK were oral contraceptives and topical anti-
fungals (miconazole), whereas in Italy (up to age 12)
oestrogens, drugs to treat incontinence, and antiseptics
were the most commonly prescribed. The percentage
of off label use of oral contraceptives and antifungals
was high in theNetherlands and theUK.Among drugs
for the nervous system, paracetamol is clearly themost
used (but probably underestimated because of high
over the counter use); methylphenidate (Netherlands
and UK), lidocaine (Netherlands), pizotifen (UK),
fluoxetine (UK) diazepam, niaprazine (Italy), and
valproic acid (Italy) were also in the top five of at least
one country. None of them was used off label, except
diazepam for children under 12 in the Netherlands. In
the group of sensory organ drugsmany different drugs
were used in the various countries, themost commonly
prescribed drugs in the Netherlands (fusidic acid,
levocabastine) and the UK (chloramphenicol) were off
label.
The low prevalence drugs comprised many classes
(groups blood, cardiovascular, hormonal, anti-
neoplastic, musculoskeletal, antiparastic). In the
blood forming organs group (B), phytomenadione,
iron, tranexamic acid, platelet inhibitors, and vitamin
K antagonists were most commonly prescribed.
Salicylic acid derivatives were off label. In the cardio-
vascular drug group topical steroids (antihaemorrhoid
creams), topical anaesthetics (lidocaine, oxetacaine), β
blockers (propranolol, atenolol), furosemide, disopyr-
amide, adrenaline (epinephrine), and enalapril were
most common. Furosemide, β blockers, adrenaline,
and topical (antihaemorrhoidal) steroids were off label
in at least one country. For the non-sex hormones,
desmopressin, oral steroids (dexamethasone, predni-
solone and prednisone), levothyroxine and glucagons)
were the most commonly prescribed drugs. Only the
oral steroids were off label (Netherlands andUKonly).
The most commonly prescribed antineoplastic and
immunomodulating drugs differed substantially
between countries but were almost always off label.
In the musculoskeletal drug group non-steroidal anti-
inflammatory drugs were the most commonly pre-
scribed, with important sequence differences between
countries but little off label use except in Italy, where
the number one and two drugs (ibuprofen and
morniflumate) were off label. In all countries the
number one antiprotozoal drug was mebendazole,
with little off label drug use.
DISCUSSION
We have provided a unique overview of primary care
prescriptionpatterns in a largemultinational European
paediatric population. The data could be used to
improve the prioritisation of research into long term
safety of paediatric drugs, as well as efficacy and
effectiveness studies in paediatric medicine. Off label
use in some of the most commonly and recurrently
Table 3 | Top 10 most commonly used therapeutic classes in various age categories
Therapeutic class (ATC) Users/1000 person years
<2 years
Antibacterials for systemic use (J01) 435
Ophthalmologicals (S01) 175
Corticosteroids, dermatological preparations (D07) 165
Drugs for obstructive airway diseases (R03) 161
Emollients and protectives (D02) 147
Analgesics (N02 134
Nasal preparations (R01) 83
Antidiarrhoeals, intestinal anti-inflammatory/anti-infective agents
(A07)
67
Stomatological preparations (A01) 59
Corticosteroids for systemic use (H02) 57
2-11 years
Antibacterials for systemic use (J01) 288
Drugs for obstructive airway diseases (R03) 108
Corticosteroids, dermatological preparations (D07 86
Emollients and protectives (D02) 67
Ophthalmologicals (S01) 64
Analgesics (N02 63
Other respiratory system products (R07) 63
Nasal preparations (R01) 38
Antibiotics and chemotherapeutics (D06) 37
Anti-inflammatory and antirheumatic products (M01) 33
12-18 years
Antibacterials for systemic use (J01) 194
Sex hormones and modulators of genital system (G03) 82
Drugs for obstructive airway diseases (R03) 71
Other respiratory system products (R07) 67
Corticosteroids, dermatological preparations (D07) 65
Anti-inflammatory and antirheumatic products (M01) 57
Nasal preparations (R01) 48
Ophthalmologicals (S01) 47
Anti-acne preparations (D10 46
Analgesics (N02) 44
ATC=WHO Anatomical Therapeutic Chemical classification system.
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Table 4 | Most commonly used drugs (use per 1000 children per year) by anatomical level and age in 2005 plus paediatric licensing status in Netherlands
Drug class and name
<2 years 2-11 years 12-18 years Total users
/1000No/1000 % off label No/1000 % off label No/1000 % off label
Alimentary tract (A)
Lactulose 92 0 332 0 58 0 482
Domperidone 79 0 222 0 73 0 374
Miconazole 200 0 30 0 8 0 238
Nystatin 130 0 11 0 3 0 144
Laurilsulfate 20 100 80 0 17 0 117
Blood and blood forming organs (B)
Ferrous fumarate 2 0 60 0 57 0 119
Phytomenadione 41 0 2 0 3 0 46
Carbasalate calcium 1 100 12 100 0 NA 13
Cardiovascular (C)
Hydrocortisone (haemorrhoids) 12 100 29 100 10 100 51
Lidocaine 3 100 30 0 13 0 46
Propranolol 0 NA 5 0 18 0 23
Adrenaline (epinephrine) 0 NA 17 0 4 0 21
Enalapril 0 NA 2 0 5 0 7
Dermatological (D)
Fusidic acid 194 100 1013 100 311 100 1518
Hydrocortisone 284 100 734 100 269 100 1287
Miconazole 273 0 337 0 204 0 814
Triamcinolone 36 100 360 100 292 100 688
Ketoconazole 48 100 168 100 139 100 355
Genitourinary system and sex hormones (G)
Levonorgestrel/oestrogen 1 100 3 100 1034 100 1038
Cyproterone/oestrogen 0 NA 4 100 321 100 325
Norethisterone 0 NA 2 100 98 100 100
Miconazole 4 100 14 100 58 100 76
Lynestrenol 0 NA 4 100 57 100 61
Systemic hormonal preparations (H)
Desmopressin 0 NA 94 0 49 0 143
Prednisolone 14 100 41 100 31 100 86
Levothyroxine sodium 1 0 13 0 16 0 30
Prednisone 0 NA 11 100 7 100 18
Dexamethasone 4 0 6 0 2 0 12
Anti-infectives for systemic use (J)
Amoxicillin 763 0 1870 0 302 0 2935
Co-amoxiclav 133 0 657 0 155 0 945
Clarithromycin 131 0 489 0 137 0 757
Azithromycin 47 0 246 0 111 0 404
Pheneticillin 22 0 211 0 161 0 394
Antineoplastic and immunomodulating agents (L)
Fluorouracil 0 NA 6 100 3 100 9
Azathioprine 0 NA 0 0 3 0 3
Triptorelin 0 NA 2 100 0 100 2
Methotrexate 0 NA 1 0 0 0 1
Ciclosporin 0 NA 1 0 0 0 1
Musculoskeletal system (M)
Diclofenac 0 NA 29 0 233 0 262
Naproxen 0 NA 10 0 171 0 181
Ibuprofen 0 NA 29 0 131 0 160
Diclofenac, combinations 0 NA 2 100 12 100 14
Bufexamac 3 100 8 100 3 100 14
Nervous system (N)
Methylphenidate 0 NA 125 0 140 0 265
Paracetamol 38 0 99 0 32 0 169
Lidocaine-prilocaine 3 0 110 0 14 0 127
Carbasalate calcium 0 NA 27 0 79 0 106
Diazepam 8 100 39 100 34 0 81
Antiparasitic drugs, insecticides, and repellents (P)
Mebendazole 1 0 87 0 14 0 102
Table 4 cont at the top of the next page
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used drugs is high (such as oral contraceptives) and
these should be considered for prioritisation.
Prioritisation of research on drug safety in paediatrics
We recommend two important assessments in prioritis-
ing research needs in medicines for children: public
health assessment,16 comprising the severity and pre-
valence of disease and the availability of treatment
alternatives; and assessment of use. This may comprise
the frequency or volume of use and the licensing/
labelling status of medicines for children. The use of off
label and unlicensedmedicines implies that there are no
proper labelling and dosing recommendations, which
can potentially be harmful to children.17-20 Therefore off
label and unlicensed medicines should be a higher
priority for research than licensed/on labelmedications,
especially if no data on safety and efficacy in children are
available. We focused on assessing the volume and
labelling status to provide knowledge to experts and
facilitate research prioritisation that includes both the
public health as well as the assessment of use.
Our data on use support the conclusions of the
recently published EMEA consensus/expert derived
list of research priorities concerning off patent medic-
inal products,16 which emphasised the need for
paediatric studies of the safety of topical, systemic,
and inhaled steroids. Steroids are associated with
impaired growth,21 abnormalities in glucose meta
bolism,22 andadrenal suppression.23 24Of these, growth
retardation is the most common and is of particular
concern in children. The extent of growth suppression
varies with the method of administration (such as
inhaledororal) and thedurationof treatment, aswell as
with the type and dose of glucocorticoid used.21 25
EMEA also lists topical and systemic antifungals
(imidazoles/triazoles), acid reducing drugs, and anti-
neoplastic drugs as research priorities. These drugs are
often or recurrently used and are mostly off label.
Many other drugs listed did not appear as commonly
useddrugs inour studyand,on thebasisof frequencyof
use in primary care alone, would not be considered as
priorities but apparently were considered priorities for
other reasons.On theotherhand, sexhormonesarenot
listed on the priority list, whereas they are commonly
and recurrently prescribed, mostly off label. Few long
term safety studies on the use of sex hormones in
adolescents are available and to our knowledge there
are no randomised controlled trials on their safety and
efficacy in this age group. The use of oral contra-
ceptives in adolescents has been associated with an
increased risk of lower bone mineral density, higher
serum cholesterol concentrations,
triglyceridaemia,26-28 cardiovascular events (such as
myocardial infarction and stroke), and venous
thromboembolism.29-33 As the use of sex hormones in
young adolescents is relatively high, leading to a long
duration of use, further studies on the efficacy and long
term safety effects of these drugs in young women are
warranted.
Although patterns of drug use and labelling status
can informdecisionsonprioritisationof research, these
data inform also us about suboptimal use and might
even uncover undesirable prescribing practices. For
example, fusidic acid and chloramphenicol are often
usedandoftenoff label (tables 4-6). In theNetherlands,
fusidic acid is prescribed for the treatment of con-
junctivitis, similar to chloramphenicol in the UK. The
beneficial effect of antibiotics in the treatment of this
condition, however, has not been proved.34 35 Indeed
acute bacterial conjunctivitis is often a self limiting
condition, and topical antibiotic use offers only
marginal benefit in improving clinical outcomes;
hence the emphasis should be on educating clinicians
not to prescribe such treatment rather than a call for
more research.36 37 Another example underlining the
need for education rather than research is the cough
and cold medications. These drugs are not only
availableover the counterbut are alsooftenprescribed,
which should be strongly discouraged because of
reports of death and lack of efficacy.38
Patterns of drug use
We found that the prevalence of the most commonly
prescribed drugs in primary care is highest in children
Drug class and name
<2 years 2-11 years 12-18 years Total users
/1000No/1000 % off label No/1000 % off label No/1000 % off label
Metronidazole 2 100 21 0 20 0 43
Proguanil, combinations 0 NA 4 0 10 0 14
Permethrin 1 0 8 0 3 0 12
Respiratory system (R)
Salbutamol 311 0 1053 0 448 0 1813
Fluticasone 159 0 702 0 201 0 1062
Desloratadine 14 0 447 0 366 0 827
Xylometazoline 154 100 356 0 143 0 654
Levocetirizine 0 NA 177 0 302 0 479
Sensory organs (S)
Fusidic acid 342 100 441 100 263 100 1049
Levocabastine 2 100 130 100 156 100 291
Hydrocortisone/anti-infectives 12 0 129 0 70 0 211
Lidocaine 33 100 135 0 16 0 185
NA=not assessable.
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Table 5 | Most commonly used drugs (use per 1000 children per year) by anatomical level and age in 2005 plus paediatric licensing status in UK
Drug class and name
<2 years 2-11 years 12-18 years Total users
/1000No/1000 % off label No/1000 % off label No/1000 % off label
Alimentary tract (A)
Lactulose 797 0 2565 0 565 0 3927
Miconazole 566 0 134 0 31 0 731
Ranitidine 145 100 133 0 343 0 622
Mebeverine 0 NA 57 0 524 0 581
Domperidone 103 0 136 0 247 0 486
Blood and blood forming organs (B)
Folic acid 141 100 48 0 368 0 558
Tranexamic acid 0 NA 9 0 295 0 304
Aspirin 12 100 52 100 37 0 103
Warfarin 1 100 17 100 25 100 46
Phytomenadione 26 0 10 0 7 0 43
Cardiovascular (C)
Adrenaline (epinephrine) 6 100 580 0 383 0 970
Propranolol 4 0 27 0 262 0 293
Furosemide 18 100 38 0 19 0 76
Atenolol 2 100 31 100 42 100 78
Enalapril 0 NA 26 0 37 0 63
Dermatological (D)
Hydrocortisone 2425 0 7311 0 2574 0 12 310
Fusidic acid 880 0 3936 0 1457 0 6273
Clobetasone butyrate 232 0 1888 0 1080 0 3200
Clotrimazole 828 100 1617 0 627 0 3073
Betamethasone 74 0 967 0 1360 0 2401
Genitourinary system and sex hormones (G)
Clotrimazole 61 100 182 100 801 0 1046
Norethisterone 0 NA 4 100 1019 100 1025
Levonorgestrel 0 NA 0 0 946 0 946
Medroxyprogestrogen 0 NA 1 100 693 0 695
Desogestrel 1 100 0 100 268 100 272
Systemic hormonal preparations (H)
Desmopressin 0 NA 467 0 312 0 779
Levothyroxine 19 0 89 0 159 0 267
Glucagon 0 NA 77 0 108 0 185
Dexamethasone 19 100 44 0 8 0 72
Somatropin 0 NA 28 0 26 0 54
Anti-infectives for systemic use (J)
Phenoxymethylpenicillin 518 0 6057 0 5710 0 12285
Flucloxacillin 897 0 6043 0 4223 0 11 163
Erythromycin 1287 0 5265 0 3386 0 9938
Trimethoprim 351 0 2623 0 2122 0 5096
Cefalexin 345 100 1597 0 1098 0 3041
Antineoplastic and immunomodulating agents (L)
Azathioprine 0 NA 16 0 65 0 81
Methotrexate 0 NA 10 0 24 0 34
Ciclosporin 0 NA 13 100 8 0 22
Tacrolimus 0 NA 5 0 9 0 14
Goserelin 0 NA 2 100 2 100 6
Musculoskeletal system (M)
Ibuprofen 1085 0 5404 0 4251 0 10 740
Diclofenac 2 0 41 0 1247 0 1290
Mefenamic acid 0 NA 11 0 1278 0 1289
Naproxen 0 NA 4 0 143 0 147
Ketoprofen 0 NA 15 100 70 0 86
Nervous system (N)
Paracetamol 4292 0 11 085 0 2832 0 18 209
Methylphenidate 0 NA 286 0 433 0 719
Pizotifen 0 NA 207 0 430 0 637
Fluoxetine 0 NA 6 0 398 0 404
Diazepam 4 0 124 0 266 0 394
Table 5 cont at the top of the next page
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agedunder2, that themost commonlyuseddrugs (anti-
infectives, dermatologicals, and respiratory drugs) are
the same in all three age categories, and that almost all
otherdrugs areusedby less than10%of childrenayear.
In general, we can categorise three groups of drug use:
drugs used by more than 10% of children a year, those
used by 1-10%, and those used by less than 1%.The use
of the high prevalence drug classes decreases with age
but remains high, whereas the use of the lowest
prevalence drug groups increases to a moderate
prevalence rate in adolescence, except in the case of
cardiovascular and antineoplastic agents. Only a few
therapeutic drug classes accounted for most use in a
specific anatomical class: antibacterials, topical corti-
costeroids, antiasthma and antianaemia medications,
cardiac drugs, sex hormones, oral corticosteroids, non-
steroidal anti-inflammatory drugs, analgesics, and
ophthalmological drugs. Relatively speaking, the
high prevalence drugs were more often used for acute
use.Only 12 drug classes (antidiabetics, digestives, bile
and liver therapy, antithrombotic agents, drugs affect-
ing the renin-angiotensin system, lipid lowering drugs,
sex hormones, thyroid therapeutic agents, immuno-
suppressive agents, muscle relaxants, antiepileptics,
and psychoanaleptics) were prescribed more often for
recurrent than acute use.
We observed an age related sex reversal: prevalence
rates for drug use were consistently higher in adoles-
cents girls than in adolescent boys (except in the case of
non-sex hormones), whereas the opposite was true in
the younger age categories. This agrees with findings
from previous Dutch and Danish studies.39 40
Interestingly, the percentage of off label use varied
highly between countries, and similar drugs differed in
off label status between countries. This confirms that
the differences in the paediatric status of the drugs,
instead of the different prescription habits or medical
cultures as postulated by many authors, represent the
real reason for the variability reported by years and
from many European studies and surveys on the off
label use in children.41
Previous studies
Our study was population based, had a large sample
size, and covered different European countries. Pre-
vious European studies have been country or region
specific and have concentrated on specific conditions,
except for studies from Sweden, the Netherlands, and
Denmark in the late 1990s and a recent Italian study
covering data from 2000-6.40 42-44 These studies took all
types of drugs into account but themethods to calculate
prevalence and ranking (on the basis of number of
dispensed boxes or user prevalence) and age ranges
varied largely, which complicates direct comparisons.
The overall results—highest drug use in lowest age
category, ranking of the most commonly used drugs
(anti-infectives, respiratory, and dermatological
drugs), and sex pattern (more prescriptions for girls
than boys after the age of 10)—are consistent with our
findings.39 40 45
Potential of multi-country database studies
We have shown the potential of studying the primary
care prescribing of awide range of drugs usingmultiple
databases. As all databases include outcome data, such
as morbidity and mortality, they can also be used for
studies of paediatric drug safety. The country specific
estimates provide insights into prescription differences
and allow a search for high prevalence countries
regarding drug prescribing.
Limitations
We captured only outpatient, primary care drug
prescriptions and not use of over the counter drugs
(which resulted in a substantial underestimation of the
use of paracetamol and phytomenadione, and poten-
tially other drugs such as cough and coldmedications).
In the Netherlands, the UK, and Italy, most health
Drug class and name
<2 years 2-11 years 12-18 years Total users
/1000No/1000 % off label No/1000 % off label No/1000 % off label
Antiparasitic drugs, insecticides, and repellents (P)
Mebendazole 24 100 1695 0 349 0 2069
Phenothrin 3 0 201 0 53 0 257
Permethrin 35 0 845 0 400 0 1280
Malathion 40 0 1088 0 372 0 1500
Respiratory system (R)
Salbutamol 1309 100 12 403 0 8321 0 22 034
Beclometasone 256 100 6332 0 3963 0 10 552
Cetirizine 24 100 3382 0 4145 0 7552
Chlorphenamine 578 0 3945 0 959 0 5482
Loratadine 1 0 1992 0 2261 0 4254
Sensory organs (S)
Chloramphenicol 4155 100 7161 0 2192 0 13 509
Cromoglicic acid 53 100 1875 0 2630 0 4559
Fusidic acid 1316 0 1951 0 540 0 3807
Nedocromil 0 NA 265 0 465 0 730
Hydrocortisone 101 100 236 0 57 0 395
NA=not assessable.
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Table 6 | Most commonly used drugs (use per 1000 children per year) by anatomical level and age in 2005 plus paediatric licensing status in Italy
Drug class and name
<2 years 2-11 years Total users
/1000No/1000 % off label No/1000 % off label
Alimentary tract (A)
Domperidone 250 0 649 0 899
Sodium fluoride 571 0 192 0 763
Cimetropium bromide 341 0 124 0 465
Nystatin 139 0 133 0 272
Lactitol 45 0 168 0 213
Blood and blood forming organs (B)
Electrolytes 124 0 151 0 275
Tranexamic acid 4 0 168 0 172
Phytomenadione 88 0 9 0 97
Ferrous gluconate 6 0 62 0 68
Ferrous sulphate 0 NA 48 0 48
Cardiovascular (C)
Epinephrine 16 0 56 0 72
Hydrocortisone 0 NA 14 0 14
Furosemide 9 0 4 0 13
Oxetacaine 0 NA 8 0 8
Disopyramide 0 NA 1 0 1
Dermatological (D)
Betamethasone/antibiotics 205 0 431 0 636
Mometasone 240 0 362 0 602
Mupirocin 90 0 313 0 403
Clotrimazole 175 100 118 100 293
Econazole 90 100 83 100 173
Genitourinary system and sex hormones (G)
Conjugated oestrogens 57 0 26 0 83
Oxybutynin 0 NA 37 0 37
Benzydamine 2 100 19 100 21
Povidone-iodine 1 100 14 100 15
Estriol 9 100 5 100 14
Systemic hormonal preparations (H)
Betamethasone 1430 0 2064 0 3494
Prednisone 5 0 240 0 245
Desmopressin 0 NA 120 0 120
Dexamethasone 18 0 6 0 24
Levothyroxine 5 0 17 0 22
Anti-infectives for systemic use (J)
Amoxicillin 2573 0 3603 0 6176
Co-amoxiclav 1760 0 4210 0 5970
Azithromycin 666 0 2616 0 3282
Clarithromycin 683 0 2385 0 3068
Aciclovir 309 0 739 0 1048
Antineoplastic and immunomodulating agents (L)
Pidotimod 11 0 80 0 91
Leuprorelin 0 NA 7 100 7
Triptorelin 0 NA 6 100 6
Methotrexate 0 NA 5 100 5
Ciclosporin 0 NA 3 100 3
Musculoskeletal system (M)
Ibuprofen 508 100 1399 100 1907
Morniflumate 118 100 446 100 564
Ketoprofen 8 0 354 0 362
Flurbiprofen 19 0 220 0 239
Niflumic acid 62 0 168 0 232
Nervous system (N)
Paracetamol 603 0 491 0 1094
Paracetamol, combinations 255 0 506 0 761
Niaprazine 158 0 39 0 197
Diazepam 41 0 85 0 126
Valproic acid 4 0 39 0 43
Table 6 cont at the top of the next page
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problems are dealt with in primary care,8 and as drug
prescriptions by a specialist for a chronic disease are
often continued by general practitioners or paediatri-
cians, most of them are picked up. Drugs given in
hospital and the monitoring of chemotherapeutic and
biological drugs areunlikely tobe fully capturedbyour
databases. Despite differences in the absolute preva-
lence rates of drug prescribing and the types of drugs
prescribed, age and sex patterns were consistent in the
three countries. As the UK accounted for 60% of the
study population, however, the pooled results are
inevitably dominated by UK prescription patterns so
we conducted stratified analyses as much as possible.
Because of the nature of the databases, we studied drug
prescriptions rather than drug intake, and so the
prevalence of actual drug exposure might be lower
than estimated here.
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